King Edward Medical University, Lahore, Pakistan.
Nishtar Medical College, Multan, Pakistan.
Crit Rev Oncol Hematol. 2021 Jan;157:103197. doi: 10.1016/j.critrevonc.2020.103197. Epub 2020 Dec 10.
Breast cancer is the most common cause of cancer-related deaths among women. There are a limited number of targeted therapies available for triple-negative breast cancer (TNBC), and chemotherapy is the mainstay of treatment. Among checkpoint inhibitors, atezolizumab is the only drug approved for PD-L1+ TNBC patients. We performed a systematic review to assess the efficacy and safety of PD-1 inhibitor pembrolizumab in triple-negative breast cancer. We included 15 clinical trials in this review. Pembrolizumab was well tolerated by all patients with triple-negative breast cancer. Pembrolizumab was more effective in the treatment of early-stage TNBC patients as compared to placebo, regardless of PD-L1 status. In advanced-stage breast cancer, pembrolizumab was as effective as single-agent chemotherapy with a better safety profile. Pembrolizumab with chemotherapy showed significantly better median progression free survival as compared to chemotherapy in advanced TNBC.
乳腺癌是女性癌症相关死亡的最常见原因。针对三阴性乳腺癌（TNBC）的靶向治疗方法有限，化疗是主要的治疗方法。在检查点抑制剂中，阿替利珠单抗是唯一批准用于 PD-L1+TNBC 患者的药物。我们进行了一项系统评价，以评估 PD-1 抑制剂帕博利珠单抗在三阴性乳腺癌中的疗效和安全性。本综述纳入了 15 项临床试验。所有三阴性乳腺癌患者对帕博利珠单抗均耐受良好。与安慰剂相比，帕博利珠单抗在治疗早期 TNBC 患者方面更有效，无论 PD-L1 状态如何。在晚期乳腺癌中，帕博利珠单抗与单药化疗疗效相当，但安全性更好。帕博利珠单抗联合化疗在晚期 TNBC 中的中位无进展生存期显著优于化疗。
